4-Nitrobenzyl(2S,4S)-4-Acetylthio-2-[[N-Sulfamoyl-N-(Tert-Butoxycarbonyl)Amino]Methyl]Pyrrolidine-1-Carboxylate (Doripenem Side-Chain)

The compound designated as 4-Nitrobenzyl (2S,4S)-4-acetylthio-2-[[N-sulfamoyl-N-(tert-butoxycarbonyl)amino]methyl]pyrrolidine-1-carboxylate serves as a protected chiral pyrrolidine side‑chain in the convergent synthesis of doripenem monohydrate, a parenteral carbapenem antibiotic. The molecule integrates a 4‑nitrobenzyl (PNB) ester at the pyrrolidine nitrogen carbamate, an S‑acetyl thioether at the 4‑position, and an N‑sulfamoyl‑N‑Boc aminomethyl substituent at the 2‑position in a defined (S,S) configuration. Commercial lots are typically supplied as a white to off‑white crystalline powder with an HPLC purity (area‑%) not less than 98.5% and an enantiomeric excess exceeding 99.0% as determined by chiral stationary‑phase chromatography. Residual solvent levels are controlled to ≤5000 ppm for ethyl acetate, ≤600 ppm for dichloromethane, and ≤300 ppm for N,N‑dimethylformamide in accordance with ICH Q3C guideline limits for Class 2 and Class 3 solvents. Water content by Karl Fischer titration is maintained at <0.5%, and sulfated ash does not exceed 0.1%. The substance is stored at ‑20 ± 5 °C under argon in amber glass containers to preserve Boc‑group integrity and to prevent ester hydrolysis; exposure to ambient humidity above 30% RH for more than 8 hours during dispensing should be avoided.

What Distinguishes the Boc‑Sulfamoyl Architecture from Other Carbapenem Side‑Chain Donors?

In contrast to the p‑nitrobenzyl (2S,4S)-4‑mercapto‑2‑(sulfamoylaminomethyl)pyrrolidine‑1‑carboxylate intermediate used in meropenem production, the doripenem side‑chain introduces a terr‑butoxycarbonyl (Boc) protection on the sulfamoyl nitrogen. This additional N‑protection directs the acylation step toward the primary sulfamoyl NH₂ after Boc removal, suppressing the formation of bis‑acylated by‑products that plague imipenem‑type side‑chains where the amino group is unprotected. The S‑acetyl moiety serves as a latent thiol, requiring mild base‑promoted deacetylation (typically with aqueous NaOH or methanolic NaOMe at 0‑5 °C for 15‑30 min) immediately prior to coupling, thereby avoiding the oxidative dimerization route commonly encountered with free thiol-containing side‑chains such as those employed in panipenem synthesis. The 4‑nitrobenzyl carbamate protecting group is orthogonal to the Boc group; it is removed under neutral hydrogenolytic conditions (H₂, 5% Pd/C, 1 atm, 25 °C) after amide bond formation, while the Boc is cleaved with trifluoroacetic acid or HCl/dioxane. This orthogonality enables a sequential deprotection strategy that isolates the reactive sulfamoyl amine last, a step critical for the final crystallization of doripenem hydrate in its thermodynamically stable Form I polymorph.

When comparing crystallization behaviour, the doripenem side‑chain ester exhibits a melting endotherm at 112–115 °C by DSC (10 °C/min, N₂ atmosphere), while the corresponding meropenem side‑chain (free sulfamoyl, no Boc) melts with decomposition above 130 °C. This lower melt onset facilitates solvent‑intensive downstream amidation in ethyl acetate or tetrahydrofuran at ‑20 to 0 °C without precipitating the side‑chain before activation, a recurring problem with high‑melting p‑nitrobenzyl esters.

Analytical Release Specifications and Pharmacopoeial Alignment

For GMP‑grade material supplied to manufacturers filing under US DMF or CEP, additional proof of absence of mutagenic 4‑nitrobenzyl chloride (limit 1.5 µg/g by LC‑MS/MS) and N‑nitrosamine impurities (≤0.03 ppm sum) is required. These limits are verified under ICH M7(R1) using AMES‑testing‑supported acceptable intakes.

At manufacturing scale, the final crystallisation from ethyl acetate/n‑heptane (1:2 v/v) coupled with a controlled cooling ramp of 0.3 °C/min from 45 °C to ‑5 °C yields a particle size distribution with D₅₀ between 15 and 30 µm as measured by laser diffraction (ISO 13320:2020). Milling to reduce D₅₀ below 10 µm has been observed to accelerate hydrolytic degradation in subsequent amidation, likely due to an increased proportion of amorphous surface content; therefore, micronisation is not recommended unless the material is to be used within 24 hours and maintained under strictly anhydrous conditions.

When Coupling to an Activated Carbapenem Nucleus, How Does Counter‑Ion Selection Influence Diastereomeric Excess?

The carboxy group of the side‑chain is typically activated in situ as a mixed anhydride using pivaloyl chloride in the presence of N‑methylmorpholine in anhydrous THF at ‑15 ± 3 °C, or via an active ester generated with 1‑hydroxybenzotriazole and a carbodiimide. The tertiary amine counter‑ion in the receiving carbapenem nucleus (free base vs. HCl salt vs. mesylate) strongly influences the diastereomeric outcome. Using the free base of the doripenem bicyclic nucleus (the enamine tautomer stabilised as a crystalline solid) in combination with a lithium or magnesium salt additive maintains the (2S,4S) configuration with diastereomeric excess routinely above 99.5%. In contrast, if the hydrochloride salt of the nucleus is employed with a trialkylamine scavenger, competing N‑alkylation at the sulfamoyl nitrogen of the side‑chain can generate a process‑critical impurity at up to 0.8–1.2%, requiring additional purification by flash chromatography, a step that reduces overall yield by 8–12% across pilot‑scale batches of 50 kg input nucleus.

Process development studies on 200 L glass‑lined reactors have demonstrated that maintaining the water content of the activation mixture below 500 ppm (as monitored by online NIR) is necessary to avoid consumption of the pivaloyl chloride by hydrolysis, which otherwise results in incomplete side‑chain activation and carry‑over of unreacted starting material into the coupling vessel. Addition rate of the acid chloride over 20–30 min with jacket temperature set to ‑25 °C prevents exotherm spikes beyond ‑8 °C, a temperature threshold above which the mixed anhydride undergoes Curtius‑type rearrangement, observed as a rapid 2–3% drop in conversion to the desired amide.

Uncontrolled Deblocking Pathways and Material Rejection Criteria

The Boc group on the sulfamoyl nitrogen is selectively labile under strongly acidic conditions, but even weakly acidic environments encountered in technical‑grade solvents can initiate partial premature deprotection during storage of solutions. In a stability‑indicating study over 14 days at 5 °C, a 0.5 M solution in acetonitrile with 0.02% (v/v) acetic acid showed 0.15% per day accumulation of the des‑Boc amine impurity, reaching the 1.0% specification limit after 7 days. Consequently, dissolution in aprotic solvents for downstream processing must be performed immediately before use, and any hold‑up in the feed line exceeding 4 hours during campaign production is grounds for rejection of that portion of the batch.

Moisture‑induced deacetylation of the thioacetate, forming free thiol and acetic acid, autocatalyzes further Boc removal and ester cleavage. On a 100 L rotary vacuum dryer at 40 °C, residual moisture above 0.8% after drying produced a thiol‑group content (Ellman’s assay) of 0.6 meq/kg relative to an acceptance threshold of ≤0.1 meq/kg. The autocatalytic cascade resulted in rejection of three consecutive batches before implementation of post‑dryer nitrogen purging with a dew point ≤‑70 °C. These incidents underscore the requirement for rigorous moisture exclusion and real‑time dew‑point monitoring on drying equipment.

At kilo‑lab scale, batch‑to‑batch variability in the residual 4‑nitrobenzyl alcohol from ester synthesis has been linked to variable hydrogenolysis kinetics in the subsequent step. Keeping the alcohol content below 0.2% (GC‑FID) avoids palladium catalyst poisoning: catalyst loadings of 5% Pd/C (5 wt%) with respect to side‑chain can be maintained for 15–20 cycles before activity drops below 90% of initial. When alcohol carryover exceeds 0.5%, catalyst consumption rises by a factor of 2.5–3.0, a cost driver in campaigns exceeding 500 kg API.

Regulatory Filing Status and Source Verification

Manufacturers filing for ANDA or 505(b)(2) applications for doripenem for injection must demonstrate side‑chain traceability through the entire synthetic route back to the (S)‑proline chiral pool. Typically, the diastereomeric purity of the trans‑4‑hydroxy‑L‑proline‑derived fragment is controlled to 99.5% de by chiral derivatisation GC before introduction of the acetylthio group via Mitsunobu inversion, ensuring the final (2S,4S) configuration. Certificates of analysis for API‑starting‑material designation per ICH Q11 should include a statement of GMP compliance from the point of introduction of the sulfamoyl‑Boc side‑chain amine. A Type II DMF is normally filed with the US FDA for the side‑chain intermediate, containing sections on general information, characterisation, and container closure systems in accordance with 21 CFR 314.420. Documentation of three consecutive validation batches at proposed commercial scale is a common request during pre‑approval inspection.

Differences from the structurally similar meropenem side‑chain are not limited to the Boc group. The meropenem counterpart, p‑nitrobenzyl (2S,4S)-2-(sulfamoylaminomethyl)-4-methylthio‑pyrrolidine‑1‑carboxylate, incorporates a methyl thioether rather than an acetylthio moiety, which remains intact throughout the coupling and deprotection sequence, obviating the deacetylation step required for doripenem. That difference translates into a narrower processing temperature window for the doripenem side‑chain activation (‑18 to ‑12 °C for the mixed anhydride, vs. ‑10 to 0 °C for meropenem’s activated ester). These distinctions directly affect reactor setup on multipurpose drug‑substance lines, where shared vessels between the two campaigns require exhaustive solvent‑swap and moisture removal protocols to avoid cross‑contamination of Boc‑protected and non‑Boc side‑chains, which co‑elute in the API’s HPLC impurity profile.